Vol. 1 No. 11 (2021)
Reimbursement Reviews

Risperidone for Extended-Release Injectable Suspension (Perseris)

Published November 9, 2021

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses risperidone for extended-release injectable suspension (Perseris), powder for suspension, 90 mg or 120 mg subcutaneous injection.
  • Indication: Treatment of schizophrenia in adults.